Review

three-component self-adjuvating immunogen v3 glycopeptide epitope; t-helper peptide p30; tlr2 ligand (ImmunoGen Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ImmunoGen Inc three-component self-adjuvating immunogen v3 glycopeptide epitope; t-helper peptide p30; tlr2 ligand
Saccharide antigens, carrier, linker/spacer of some of the glycoconjugate vaccine described in this manuscript.

Saccharide antigens, carrier, linker/spacer of some of the glycoconjugate vaccine described in this manuscript.

Three Component Self Adjuvating Immunogen V3 Glycopeptide Epitope; T Helper Peptide P30; Tlr2 Ligand, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/three-component+glycopeptide+immunogen/pmc09542079-28-18-11?v=ImmunoGen+Inc
Average 90 stars, based on 1 article reviews

three-component self-adjuvating immunogen v3 glycopeptide epitope; t-helper peptide p30; tlr2 ligand - by Bioz Stars, 2026-08

90/100 stars

Images

1) Product Images from "Recent advances on smart glycoconjugate vaccines in infections and cancer"

Article Title: Recent advances on smart glycoconjugate vaccines in infections and cancer

Journal: The Febs Journal

doi: 10.1111/febs.15909

Figure Legend Snippet: Saccharide antigens, carrier, linker/spacer of some of the glycoconjugate vaccine described in this manuscript.

Techniques Used: Conjugation Assay, Glycoproteomics, Membrane

Structures of: 8 unimolecular pentavalent vaccine containing MUC antigens together with the Globo‐H, and GM2 ganglioside [ , , ]; 9 TACA‐MUC1 glycopeptide conjugated with TT as a carrier protein , 10 which contains four copies of Tn antigen, a Th epitope, a CTL epitope, and a TLR2 ligand were combined in a glycoconjugate construct ; 11 MUC1‐TF and sTn glycopeptides conjugated to Qβ ; TACA antigens conjugated to PS A1 ( 12 ) and PS B ( 13 ) . Qβ conjugate image is reproduced from Ref. . Copyright 2019 American Chemical Society.

Figure Legend Snippet: Structures of: 8 unimolecular pentavalent vaccine containing MUC antigens together with the Globo‐H, and GM2 ganglioside [ , , ]; 9 TACA‐MUC1 glycopeptide conjugated with TT as a carrier protein , 10 which contains four copies of Tn antigen, a Th epitope, a CTL epitope, and a TLR2 ligand were combined in a glycoconjugate construct ; 11 MUC1‐TF and sTn glycopeptides conjugated to Qβ ; TACA antigens conjugated to PS A1 ( 12 ) and PS B ( 13 ) . Qβ conjugate image is reproduced from Ref. . Copyright 2019 American Chemical Society.

Techniques Used: Glycoproteomics, Construct

Structures of: 16 glycoconjugate vaccine containing tandem repeating unit of MUC‐1 conjugated to the TLR2 ligand ; 17 glycoconjugate vaccine containing a TACA antigen (sTn, GM3, Globo‐H) conjugated to a TLR‐4 ligand [ , , ], 18 a synthetic Tn antigen‐glycolipid containing an α‐GalCer residue ; 19 Au nanoconstructs, containing the TF disaccharide antigen instead of the Tn antigen. Figure of compound 19 reproduced from Ref. . Copyright 2012, American Chemical Society.

Figure Legend Snippet: Structures of: 16 glycoconjugate vaccine containing tandem repeating unit of MUC‐1 conjugated to the TLR2 ligand ; 17 glycoconjugate vaccine containing a TACA antigen (sTn, GM3, Globo‐H) conjugated to a TLR‐4 ligand [ , , ], 18 a synthetic Tn antigen‐glycolipid containing an α‐GalCer residue ; 19 Au nanoconstructs, containing the TF disaccharide antigen instead of the Tn antigen. Figure of compound 19 reproduced from Ref. . Copyright 2012, American Chemical Society.

Techniques Used: Residue

Image Search Results

Journal: The Febs Journal

Article Title: Recent advances on smart glycoconjugate vaccines in infections and cancer

doi: 10.1111/febs.15909

Figure Lengend Snippet: Saccharide antigens, carrier, linker/spacer of some of the glycoconjugate vaccine described in this manuscript.

Article Snippet: Man 9 GlcNAc 2 at N334 V3 antigen , Three‐component self‐adjuvating immunogen: V3 glycopeptide epitope; T‐helper peptide P30; TLR2 ligand , , Amide coupling and copper‐catalyzed azide‐alkyne cycloaddition (CuAAC) , [ ] .

Techniques: Conjugation Assay, Glycoproteomics, Membrane

Journal: The Febs Journal

Article Title: Recent advances on smart glycoconjugate vaccines in infections and cancer

doi: 10.1111/febs.15909

Figure Lengend Snippet: Structures of: 8 unimolecular pentavalent vaccine containing MUC antigens together with the Globo‐H, and GM2 ganglioside [ , , ]; 9 TACA‐MUC1 glycopeptide conjugated with TT as a carrier protein , 10 which contains four copies of Tn antigen, a Th epitope, a CTL epitope, and a TLR2 ligand were combined in a glycoconjugate construct ; 11 MUC1‐TF and sTn glycopeptides conjugated to Qβ ; TACA antigens conjugated to PS A1 ( 12 ) and PS B ( 13 ) . Qβ conjugate image is reproduced from Ref. . Copyright 2019 American Chemical Society.

Techniques: Glycoproteomics, Construct

Journal: The Febs Journal

Article Title: Recent advances on smart glycoconjugate vaccines in infections and cancer

doi: 10.1111/febs.15909

Figure Lengend Snippet: Structures of: 16 glycoconjugate vaccine containing tandem repeating unit of MUC‐1 conjugated to the TLR2 ligand ; 17 glycoconjugate vaccine containing a TACA antigen (sTn, GM3, Globo‐H) conjugated to a TLR‐4 ligand [ , , ], 18 a synthetic Tn antigen‐glycolipid containing an α‐GalCer residue ; 19 Au nanoconstructs, containing the TF disaccharide antigen instead of the Tn antigen. Figure of compound 19 reproduced from Ref. . Copyright 2012, American Chemical Society.

Techniques: Residue

Chemoenzymatic synthesis of HIV-1 A244 V3 glycopeptides: (a) synthesis of A244 V3 glycopeptides carrying a high-mannose or a complex-type N-glycan at the N334 site; (b) structures of additional synthetic A244 V3 peptides and glycopeptides carrying a high-mannose or a complex-type N-glycan at the N301 and N295 sites.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: Chemoenzymatic synthesis of HIV-1 A244 V3 glycopeptides: (a) synthesis of A244 V3 glycopeptides carrying a high-mannose or a complex-type N-glycan at the N334 site; (b) structures of additional synthetic A244 V3 peptides and glycopeptides carrying a high-mannose or a complex-type N-glycan at the N301 and N295 sites.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Glycoproteomics

SPR sensorgrams of binding to A244 V3 high-mannose glycopeptides (3, 6, and 8) by bNAb PGT128, 10-1074, and PGT126.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: SPR sensorgrams of binding to A244 V3 high-mannose glycopeptides (3, 6, and 8) by bNAb PGT128, 10-1074, and PGT126.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Binding Assay

Synthesis of three-component HIV immunogen containing the A244 V3 N334 high-mannose glycopeptide.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: Synthesis of three-component HIV immunogen containing the A244 V3 N334 high-mannose glycopeptide.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Glycoproteomics

Comparison of the binding of the antisera and selected bNAbs to an array of HIV-1 gp120/gp140 envelope glycoproteins: (a) antisera from the A244 glycopeptide immunogen; (b) antibody PGT128; (c) antibody 10-1074. The HIV-1 A244 gp120 carries an N-glycan at the N334 site, while HIV-1 JR-FL gp140, CN54 gp120, and MCON gp120 have an N-glycan at the N332 site.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: Comparison of the binding of the antisera and selected bNAbs to an array of HIV-1 gp120/gp140 envelope glycoproteins: (a) antisera from the A244 glycopeptide immunogen; (b) antibody PGT128; (c) antibody 10-1074. The HIV-1 A244 gp120 carries an N-glycan at the N334 site, while HIV-1 JR-FL gp140, CN54 gp120, and MCON gp120 have an N-glycan at the N332 site.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Comparison, Binding Assay, Glycoproteomics

ELISA analysis of the binding of the antisera and antibody PGT128 to synthetic A244 V3 glycopeptides: (a–c) ELISA binding of the rabbit antisera to A244 V3 glycopeptides; (d–f) ELISA binding of the pretreated (V3 peptide-depressed) rabbit sera to A244 V3 glycopeptides; (g–i) ELISA binding of PGT128 to A244 V3 glycopeptides.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: ELISA analysis of the binding of the antisera and antibody PGT128 to synthetic A244 V3 glycopeptides: (a–c) ELISA binding of the rabbit antisera to A244 V3 glycopeptides; (d–f) ELISA binding of the pretreated (V3 peptide-depressed) rabbit sera to A244 V3 glycopeptides; (g–i) ELISA binding of PGT128 to A244 V3 glycopeptides.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay

ELISA analysis of the binding of the antisera with additional HIV-1 V3 glycopeptides and free high-mannose N-glycans: (a) ELISA binding of the pretreated sera to A244 N334 high-mannose glycopeptide with different length of the peptide backbone; (b) ELISA binding of the pretreated sera to different V3 N332 high-mannose glycopeptides.

Journal: Journal of medicinal chemistry

Article Title: Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N -Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition

doi: 10.1021/acs.jmedchem.8b01290

Figure Lengend Snippet: ELISA analysis of the binding of the antisera with additional HIV-1 V3 glycopeptides and free high-mannose N-glycans: (a) ELISA binding of the pretreated sera to A244 N334 high-mannose glycopeptide with different length of the peptide backbone; (b) ELISA binding of the pretreated sera to different V3 N332 high-mannose glycopeptides.

Article Snippet: The synthetic three-component A244 glycopeptide immunogen 15 was incorporated into liposome following a reported procedure.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Glycoproteomics

Review

Structured Review

Images

1) Product Images from "Recent advances on smart glycoconjugate vaccines in infections and cancer"

Similar Products

Image Search Results